2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2886

Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies
Abstract Number: 2568

Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
Abstract Number: 2608

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study
Abstract Number: 1189

Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis from Korean Perspective
Abstract Number: 936

Selective Deficiency of Serine Arginine-Rich Splicing Factor 1 (SRSF1) in T Lymphocytes Leads to mTORC1 Activation, Treg Dysfunction and Systemic Autoimmune Disease
Abstract Number: 2683

Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE
Abstract Number: 2174

Self-Report of Fracture History Compared to Fracture Codes from an Electronic Health Record Dataset
Abstract Number: 1950

Self-Reported Depression and Anxiety Among US Adults Aged 18-44 Years with Arthritis, National Health Interview Survey 2014-2016
Abstract Number: 489

Self-Reported Depression in Patients with Rheumatoid Arthritis Is Undertreated and Associated with Poorer Clinical Status and Lower Rates of Remission in Routine Care
Abstract Number: 715

Septic Shock Among Patients with Systemic Lupus Erythematosus: Short and Long-Term Outcome and Cost. Analysis of the French Nationwide Database
Abstract Number: 1976

Sequencing of the MHC Region Defines HLA-DQA1 As Driven Risk for Anti-Citrullinated Protein Antibodies (ACPA)-Positive Rheumatoid Arthritis in Han Population
Abstract Number: 1091

Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is Essential for T Lymphocyte Homeostasis and Decreased Levels of SRSF1 Correlate with Lymphopenia in SLE Patients
Abstract Number: 1637

Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis
Abstract Number: 1093

Serologic Evidence Linking Epstein Barr Virus Reactivation, Heightened Interferon Pathway Activation and Increased Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 1221

Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].